Open AccessPB1863: BRUIN CLL‐322: A PHASE 3 OPEN‐LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
Author(s) -
Mato A. R.,
Wierda W. G.,
Pagel J. M.,
Davids M. S.,
Zinzani P. L.,
Lu Y.,
Liu H.,
Shahda S.,
Leow C. C.,
Tam C. S.,
Woyach J. A.,
Eyre T. A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850304.03677.28
Subject(s) - venetoclax , rituximab , ibrutinib , population , regimen , chronic lymphocytic leukemia , bruton's tyrosine kinase , context (archaeology) , medicine , oncology , leukemia , lymphoma , tyrosine kinase , biology , paleontology , receptor , environmental health